Gapping up
In reaction to strong earnings/guidance:
- TTD +24.9%, IMMR +14.4%, OMER +11.6%, GLOB +7.8%, MCFT +6.8%, VRAY +5.9%, NDLS +5.8%, FSCT +5.6%, UEPS +5.6%, ARCB +5.5%, PPC +4.5%, ASYS +4.1%, KTOS +3.7%, TRI +3.3%, MT +2.2%, RICK +1.5%, AVID +1.2%, SSRM +0.7%, HUBS +0.7%
Other news:
- AKCA +16.2% (Akcea Therapeutics confirms FDA Advisory Committee votes in favor of WAYLIVRA for treatment of familial chylomicronemia syndrome)
- IONS +4.1% (confirms FDA Advisory Committee votes in favor of WAYLIVRA for treatment of familial chylomicronemia syndrome)
- XRX +2.3% (attributed to CNBC mention on Fast Money)
- MOS +1.5% (appoints Gregory Ebel to succeed Robert Lumpkins as Chairman; names Clint Freeland as CFO effective June 4; upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- CHRW +0.6% (increases share repurchase authorization by $15 mln shares of common stock)
Analyst comments:
- SRPT +2.1% (upgraded to Overweight from Equal Weight at Barclays)
- VZ +1.6% (upgraded to Overweight from Neutral at JP Morgan)
